AU2055300A - Methods for detection and use of differentially expressed genes in disease states - Google Patents

Methods for detection and use of differentially expressed genes in disease states

Info

Publication number
AU2055300A
AU2055300A AU20553/00A AU2055300A AU2055300A AU 2055300 A AU2055300 A AU 2055300A AU 20553/00 A AU20553/00 A AU 20553/00A AU 2055300 A AU2055300 A AU 2055300A AU 2055300 A AU2055300 A AU 2055300A
Authority
AU
Australia
Prior art keywords
detection
methods
disease states
differentially expressed
expressed genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU20553/00A
Inventor
Deborah L. Damm
Alison Joly
John A. Lewicki
George F. Schreiner
Lawrence W. Stanton
R. Tyler White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scios LLC
Original Assignee
Scios LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios LLC filed Critical Scios LLC
Publication of AU2055300A publication Critical patent/AU2055300A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU20553/00A 1998-12-18 1999-12-15 Methods for detection and use of differentially expressed genes in disease states Abandoned AU2055300A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11300898P 1998-12-18 1998-12-18
US60113008 1998-12-18
PCT/US1999/029941 WO2000035473A2 (en) 1998-12-18 1999-12-15 Methods for detection and use of differentially expressed genes in disease states

Publications (1)

Publication Number Publication Date
AU2055300A true AU2055300A (en) 2000-07-03

Family

ID=22347087

Family Applications (1)

Application Number Title Priority Date Filing Date
AU20553/00A Abandoned AU2055300A (en) 1998-12-18 1999-12-15 Methods for detection and use of differentially expressed genes in disease states

Country Status (3)

Country Link
EP (1) EP1140137A2 (en)
AU (1) AU2055300A (en)
WO (1) WO2000035473A2 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2360282A (en) * 2000-03-17 2001-09-19 Bioinvent Int Ab Making and using micro-arrays of biological materials
EP1275717A4 (en) * 2000-03-29 2004-10-06 Kyowa Hakko Kogyo Kk Proliferative glomerular nephritis-associated gene
US6800455B2 (en) 2000-03-31 2004-10-05 Scios Inc. Secreted factors
AU2001281322A1 (en) * 2000-07-13 2002-01-30 Biogen, Inc. Methods of identifying renal protective factors
WO2002020055A1 (en) * 2000-09-08 2002-03-14 Daiichi Suntory Pharma Co., Ltd. Remedies for heart failure
AU2002218026A1 (en) 2000-11-09 2002-05-21 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
EP1353178A4 (en) * 2000-12-22 2004-07-14 Chugai Pharmaceutical Co Ltd High-throughput screening system by microarray
AU2001286171B2 (en) * 2001-05-25 2008-01-10 Serono Genetics Institute S.A. Human CDNAs and proteins and uses thereof
US7087727B2 (en) 2001-08-13 2006-08-08 Dana-Farber Cancer Institute, Inc. Periostin-based diagnostic assays
GB0120238D0 (en) * 2001-08-20 2001-10-10 Univ College Of London Sodium channel regulators and modulators
EP1434876A4 (en) * 2001-09-11 2005-05-25 Univ Colorado Regents Expression profiling in the intact human heart
DK2336359T3 (en) 2002-05-09 2016-05-30 Brigham & Womens Hospital 1L1RL-1 as cardiovascular disease marker
AU2003295598B2 (en) * 2002-11-15 2009-12-24 Genomic Health, Inc. Gene expression profiling of EGFR positive cancer
JP2006517092A (en) * 2002-11-27 2006-07-20 アルテシアン セラピューティック，インコーポレイティド Heart failure gene determination and therapeutic drug screening
EP1644027B1 (en) 2003-07-16 2014-04-09 Evotec International GmbH Use of pleiotrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
WO2005033132A2 (en) 2003-10-03 2005-04-14 Genentech, Inc. Igf binding proteins
JP5139811B2 (en) * 2004-12-08 2013-02-06 アベンティス・ファーマスーティカルズ・インコーポレイテツド Method for measuring docetaxel resistance or sensitivity
WO2006085482A1 (en) * 2005-02-10 2006-08-17 Riken Self-replication factor and amplification method of hematopoietic stem cell
EP2605018A1 (en) 2006-03-09 2013-06-19 The Trustees of the Boston University Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
PL2386860T4 (en) 2006-04-24 2015-09-30 Critical Care Diagnostics Inc Predicting mortality and detecting severe disease
EP2482078B1 (en) 2006-05-01 2016-02-03 Critical Care Diagnostics, Inc. Diagnosis of cardiovascular disease
WO2007130627A2 (en) 2006-05-04 2007-11-15 The Brigham And Women's Hospital, Inc. Il-33 in the treatment and diagnosis of diseases and disorders
WO2008089994A1 (en) * 2007-01-25 2008-07-31 Roche Diagnostics Gmbh Use of igfbp-7 in the assessment of heart failure
WO2009117791A2 (en) * 2008-03-28 2009-10-01 Katholieke Universiteit Leuven Mucosal gene signatures
DK2827152T3 (en) 2008-04-18 2016-09-12 Critical Care Diagnostics Inc PREDICTION OF RISK OF MAJOR ADVERSE HEART EVENTS
BRPI0913514A2 (en) * 2008-09-08 2019-09-24 Ottawa Hospital Research Institute periostin-induced pancreatic regeneration
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
EP2513336B1 (en) * 2009-12-16 2016-03-02 Hitachi Chemical Co., Ltd. Method for characterizing host immune function by ex vivo induction of offensive and defensive immune markers
EP2531614B1 (en) * 2010-02-05 2018-07-18 The Procter and Gamble Company Transcriptional profiling and biomarker-based methods for identifying and evaluating agents for antioxidant efficacy in cosmetic skin care formulations
WO2011140125A1 (en) 2010-05-07 2011-11-10 Hitachi Chemical Co., Ltd. Methods of characterizing host responsiveness to interferon by ex vivo induction of interferon-responsive markers
US20140031250A1 (en) 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
EP2686689B1 (en) 2011-03-17 2019-08-07 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
CN104011543B (en) * 2011-10-24 2016-06-15 通用医疗公司 The biomarker of cancer
SG11201406184XA (en) * 2012-03-30 2014-10-30 Genentech Inc Diagnostic methods and compositions for treatment of cancer
IN2015DN01767A (en) 2012-08-21 2015-05-29 Critical Care Diagnostics Inc
WO2015063244A1 (en) * 2013-10-30 2015-05-07 Servicio Andaluz De Salud Epithelial-mesenchymal transition in circulating tumor cells (ctcs) negatives for cytokeratin (ck) expression in patients with non-metastatic breast cancer
WO2015175305A1 (en) * 2014-05-12 2015-11-19 Janssen Pharmaceutica Nv Biological markers for identifying patients for treatment with abiraterone acetate
US20170248579A1 (en) * 2014-09-10 2017-08-31 The Uab Research Foundation Amyotrophic lateral sclerosis (als) biomarkers and uses thereof
FI3198035T3 (en) 2014-09-26 2023-01-31 Methods for predicting drug responsiveness
EP3212809A1 (en) * 2014-10-29 2017-09-06 Avon Products, Inc. Screening method for identifying active agents
US20160199399A1 (en) * 2015-01-09 2016-07-14 Medical Prognosis Institute A/S Methods for predicting drug responsiveness in cancer patients
US20180037956A1 (en) * 2015-03-04 2018-02-08 Hummingbird Diagnostics Gmbh Signature of health
US11028443B2 (en) 2015-08-31 2021-06-08 Showa Denko Materials Co., Ltd. Molecular methods for assessing urothelial disease
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
US10865412B2 (en) * 2016-11-04 2020-12-15 Ottawa Heart Institute Research Therapeutics targeting IGFBP7 for the treatment or prevention of heart failure and metabolic diseases
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
US20200110073A1 (en) * 2018-10-04 2020-04-09 The Jackson Laboratory Renal disease targets

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07132095A (en) * 1993-06-11 1995-05-23 Nawata Arata Dna and protein coded thereby
AU3126595A (en) * 1994-07-18 1996-02-16 Georgetown University Antisense oligonucleotides of pleiotrophin
ID27813A (en) * 1998-01-28 2001-04-26 Corixa Corp COMPOUNDS FOR THERAPY AND DIAGNOSIS OF LUNG CANCER AND METHODS FOR USE

Also Published As

Publication number Publication date
WO2000035473A2 (en) 2000-06-22
WO2000035473A3 (en) 2000-11-09
EP1140137A2 (en) 2001-10-10

Similar Documents

Publication Publication Date Title
AU2055300A (en) Methods for detection and use of differentially expressed genes in disease states
AUPP784398A0 (en) Kidney disease detection and treatment
GB2325765B (en) Data hiding and detection methods
AU1603199A (en) Methods and devices for measuring differential gene expression
AU1807300A (en) Detection of loss of heterozygosity in tumor and serum of melanoma patients
AU3364099A (en) Diagnosis of disease state using mrna profiles in peripheral leukocytes
AU2001288249A1 (en) Biosensors and methods for their use
AU1047901A (en) Methods of genetic cluster analysis and use thereof
AU5691699A (en) Human genes differentially expressed in colorectal cancer
AU6534898A (en) Detection of double-stranded dna in a homogeneous solution
AU2001285018A1 (en) Nucleic acids and corresponding proteins entitled 83p2h3 and catrf2e11 useful in treatment and detection of cancer
AU4668196A (en) Detection of mutations or variations in dna
AU1083501A (en) Antibiotic-metal complex and methods
AU3454899A (en) Methods of separation and detection
AU2001234775A1 (en) Direct detection and mutation analysis of low copy number nucleic acids
AU4825699A (en) Identification and use of differentially expressed genes and polynucleotide sequences
AU4152200A (en) Sensing system and use thereof
AU2001235829A1 (en) Mutations in spink5 responsible for netherton's syndrome and atopic diseases
AU2001241709A1 (en) Molecules for disease detection and treatment
AU4328399A (en) Nucleic acid-cobalamin complexes and their use in gene therapy
AU6629298A (en) Interactions of skn7 gene and its use in assay methods
AU2584699A (en) Immediate early genes and methods of use therefor
AU8271998A (en) Methods of disease detection
AU3187399A (en) Mutations in mitotic check point genes and methods of diagnosis
AU5962599A (en) Detection of mutations in nucleic acids

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase